This was observed in a Phase I clinical trial investigating the impact of the mTOR inhibitor, Rapamycin, in PTEN-deficient glioblastoma; the drug proved effective in suppressing disease progression in some patients but appeared to accelerated disease in others [64]. This evidence concerns the gene MTOR and glioblastoma.